Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CH3O6P2.3Na |
| Molecular Weight | 241.9478 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[Na+].OP([O-])(=O)CP([O-])([O-])=O
InChI
InChIKey=SFDBJFMMXUVCFG-UHFFFAOYSA-K
InChI=1S/CH6O6P2.3Na/c2-8(3,4)1-9(5,6)7;;;/h1H2,(H2,2,3,4)(H2,5,6,7);;;/q;3*+1/p-3
DescriptionCurator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9635
Curator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9635
Medronic acid (conjugate base, medronate) is a diagnostic agent that is used in complex with technetium Tc-99m for imaging delineate areas of altered osteogenesis. Upon administration the complex binds to hydroxyapatite crystals in bone.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Hydroxyapatite crystals in bone |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | CIS-MDP Approved UseTechnetium Tc 99m Medronate Injection may be used as a bone imaging agent to delineate areas of altered osteogenesis. Launch Date1979 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10000 uCi single, intravenous Recommended Dose: 10000 uCi Route: intravenous Route: single Dose: 10000 uCi Sources: |
unhealthy |
Disc. AE: Allergic rash... AEs leading to discontinuation/dose reduction: Allergic rash Sources: |
16.5 mg 1 times / day multiple, intravenous Dose: 16.5 mg, 1 times / day Route: intravenous Route: multiple Dose: 16.5 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Leukocytopenia, Anemia... Other AEs: Leukocytopenia (1.7%) Sources: Anemia (5.1%) Nausea (1.7%) Elevated liver enzymes (3.4%) Oral ulceration (1.7%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Allergic rash | Disc. AE | 10000 uCi single, intravenous Recommended Dose: 10000 uCi Route: intravenous Route: single Dose: 10000 uCi Sources: |
unhealthy |
| Leukocytopenia | 1.7% | 16.5 mg 1 times / day multiple, intravenous Dose: 16.5 mg, 1 times / day Route: intravenous Route: multiple Dose: 16.5 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea | 1.7% | 16.5 mg 1 times / day multiple, intravenous Dose: 16.5 mg, 1 times / day Route: intravenous Route: multiple Dose: 16.5 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| Oral ulceration | 1.7% | 16.5 mg 1 times / day multiple, intravenous Dose: 16.5 mg, 1 times / day Route: intravenous Route: multiple Dose: 16.5 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| Elevated liver enzymes | 3.4% | 16.5 mg 1 times / day multiple, intravenous Dose: 16.5 mg, 1 times / day Route: intravenous Route: multiple Dose: 16.5 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| Anemia | 5.1% | 16.5 mg 1 times / day multiple, intravenous Dose: 16.5 mg, 1 times / day Route: intravenous Route: multiple Dose: 16.5 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Photo-induced lipid peroxidation of erythrocyte membranes by a bis-methanophosphonate fullerene. | 2007-12 |
|
| Effect of age and gender on the number and distribution of sites in Paget's disease of bone. | 2007-07 |
|
| PET-CT in pediatric Langerhans cell histiocytosis. | 2007-07 |
|
| Exposure of veterinary personnel to ionising radiation during bone scanning of horses by nuclear scintigraphy with 99mtechnetium methylene diphosphonate. | 2007-06-16 |
|
| Ewing's sarcoma of the third metatarsal: a case report and review of the literature. | 2007-06-15 |
|
| Bisphosphonate rescue in distraction osteogenesis: a case series. | 2007-06 |
|
| Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. | 2007-05 |
|
| Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. | 2007-05 |
|
| Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. | 2007-02-20 |
|
| Rapid characterization of alkylpolyphosphonates by CZE with indirect photometric and mass spectrometric detection. | 2007-02 |
|
| [Methylenebisphosphonic acid alters the pattern of pericellular glycosaminoglycans and binding properties of CD44 in human endothelial cells]. | 2007-01-24 |
|
| Metabolic fingerprints of altered brain growth, osmoregulation and neurotransmission in a Rett syndrome model. | 2007-01-17 |
|
| Abnormalities in bone mineral density distribution and bone scintigraphy in patients with childhood onset hypopituitarism. | 2007-01-15 |
|
| ATP as effector of inorganic pyrophosphatase of Escherichia coli. The role of residue Lys112 in binding effectors. | 2007-01 |
|
| Binding of substrate at the effector site of pyrophosphatase increases the rate of its hydrolysis at the active site. | 2007-01 |
|
| Safety considerations with bisphosphonates for the treatment of osteoporosis. | 2007 |
|
| [Effect of calixarene-phosphonic acid on Na+, K+-ATPase activity in plasma membranes of the smooth-muscle cells]. | 2006-12-07 |
|
| Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. | 2006-12 |
|
| Influence of phosphonation and phosphation on surface acid-base and morphological properties of CaO as investigated by in situ FTIR spectroscopy and electron microscopy. | 2006-11-01 |
|
| Acid resistance of erbium-doped yttrium aluminum garnet laser-treated and phosphoric acid-etched enamels. | 2006-11 |
|
| Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase. | 2006-10-16 |
|
| Novel chikungunya virus variant in travelers returning from Indian Ocean islands. | 2006-10 |
|
| Cytotoxic and genotoxic effects induced by stannous chloride associated to nuclear medicine kits. | 2006-10 |
|
| Growth modification of the mandible with ultrasound in baboons: a preliminary report. | 2006-10 |
|
| Metastatic pulmonary calcification in a dialysis patient: case report and a review. | 2006-10 |
|
| Nuclear medicine methods for evaluation of skeletal infection among other diagnostic modalities. | 2006-09 |
|
| Solitary bone metastasis beneath the shoulder shield: coincidence or cause? | 2006-08 |
|
| Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm. | 2006-08 |
|
| Synthesis of trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid and its radiolabelling with 99mTc for the detection of skeletal metastases. | 2006-08 |
|
| Synthesis and characterization of octa- and hexanuclear polyoxomolybdate wheels: role of the inorganic template and of the counterion. | 2006-07-24 |
|
| Monoglycosyl, diglycosyl, and dinucleoside methylenediphosphonates: direct synthesis and antiviral activity. | 2006-07-03 |
|
| The role of SPECT/CT with 99mTc-MDP image fusion to diagnose temporomandibular dysfunction. | 2006-02 |
|
| The internal thoracic artery skeletonization study: a paired, within-patient comparison [NCT00265499]. | 2006-01-05 |
|
| Use of scintigraphy for diagnosis of equine paranasal sinus disorders. | 2006-01 |
|
| Characterization of industrial alkylpolyphosphonates by infusion electrospray ionization-ion trap mass spectrometry with identification of the impurities by tandem capillary zone electrophoresis. | 2006-01 |
|
| Synthesis and antiviral evaluation of alkoxyalkyl esters of phosphonopropoxymethyl-guanine and phosphonopropoxymethyl-diaminopurine. | 2006 |
|
| Voltammetry as a virtual potentiometric sensor in modelling of a metal-ligand system and refinement of stability constants. Part 4. An electrochemical study of NiII complexes with methylene diphosphonic acid. | 2005-12 |
|
| Biochemical and imaging alterations of renal bone disease in newly detected predialysis and on maintenance dialysis patients. | 2005-10 |
|
| Three-level bilateral pediculolysis following osteoporotic lumbar compression fracture. | 2005-09-08 |
|
| [A cationic cluster of amino acid residues of inorganic pyrophosphatase from Escherichia coli as a possible site of effector binding]. | 2005-07-12 |
|
| Cyclic ADP-ribose analogues containing the methylenebisphosphonate linkage: effect of pyrophosphate modifications on Ca2+ release activity. | 2005-06-16 |
|
| Effects of radiosynovectomy with p-32 colloid therapy in hemophilia and rheumatoid arthritis. | 2005-06 |
|
| Technetium-99m diphosphonate imaging of psammocarcinoma of probable ovarian origin: case report and literature review. | 2005-06 |
|
| Solid-state molecular organization and solution behavior of methane-1,1-diphosphonic acid derivatives of heterocyclic amines: the role of the topochemical ring modification and the intramolecular hydrogen bonds in monosubstituted piperid-1-ylmethane-1,1-diphosphonic acids. | 2005-04-08 |
|
| Metal-free PPi activates hydrolysis of MgPPi by an Escherichia coli inorganic pyrophosphatase. | 2005-01 |
|
| 31P MRS analysis of the phospholipid composition of normal human peripheral blood mononuclear cells (PBMC). | 2005 |
|
| Calix[4]arene methylenebisphosphonic acids as calf intestine alkaline phosphatase inhibitors. | 2004-11-07 |
|
| Solid-state coordination chemistry of the oxomolybdate-organodiphosphonate/nickel-organoimine system: structural influences of the secondary metal coordination cation and diphosphonate tether lengths. | 2004-11-01 |
|
| [Menopause in 2004: "hormone replacement therapy" is not what it used to be anymore]. | 2004-11 |
|
| Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate. | 2004-10-04 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
39478-93-8
Created by
admin on Mon Mar 31 21:58:44 GMT 2025 , Edited by admin on Mon Mar 31 21:58:44 GMT 2025
|
PRIMARY | |||
|
3352186
Created by
admin on Mon Mar 31 21:58:44 GMT 2025 , Edited by admin on Mon Mar 31 21:58:44 GMT 2025
|
PRIMARY | |||
|
5IE00X21WX
Created by
admin on Mon Mar 31 21:58:44 GMT 2025 , Edited by admin on Mon Mar 31 21:58:44 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
